ConvaTec Group PLC Company Analysis & Research
ConvaTec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. The company serves patients with chronic conditions requiring ongoing medical device solutions across multiple care environments.
The company focuses on chronic care, which translates into an ongoing stream of revenue from relatively concentrated global markets. Convatec's well-established footprint in the US ostomy market has paved the way to forge contracts with large group purchasing organizations, including Premier and Vizient.
Company Overview
Founded: 1978. Headquarters: London, UK. Revenue: $2.28B. Market Cap: $6.49B. Ticker: CTEC (LSE).
Industry
Medical Devices & Healthcare Solutions
Cyborg Score: 7/10 — Strong
The company maintained its medium-term targets of 5–7% annual organic growth and mid-20s margins by 2026–27.
ConvaTec reaffirmed its 2026 target for double-digit adjusted EPS growth and further margin expansion. Three new wound care products (ConvaNioX, ConvaFiber, ConvaVac) and other pipeline launches are planned for 2026, with ConvaNioX seen as a major long-term opportunity. Strategic momentum supported by strong product innovation pipeline.
Key Strategic Insights for ConvaTec Group PLC
- Trading remained strong across all divisions with all four segments – Advanced Wound Care, Ostomy Care, Continence Care and Infusion Care – growing as fast or faster than in the first half.
- Major product launches planned for 2026 including ConvaNioX, ConvaFiber, and ConvaVac with ConvaNioX as a long-term opportunity.
- Secured first US Ostomy GPO contract in over five years and extended another key contract by three years.
- Management noted confidence in delivering profit growth even under a tougher US reimbursement scenario for its wound care business.
Recent Developments
- (November 2025) Reaffirmed double-digit adjusted EPS growth target and narrowed 2025 organic revenue guidance to 6.0-6.5%
- (October 2025) Secured first US Ostomy GPO contract in over five years
- (2026 Outlook) Three new wound care products planned including ConvaNioX, ConvaFiber, ConvaVac
Competitors & Competitive Landscape
- Coloplast — Leading ostomy and continence care competitor
- Zimmer Biomet Holdings — Medical devices and orthopedic solutions
- Joerns Healthcare — Pressure relief and patient mobility
- Urgo Medical — Wound care and advanced dressings
The company lagged significantly behind key competitor Coloplast. Zimmer Biomet Holdings, Joerns Healthcare, Globus Medical, Urgo Medical, and Corin Group are some competitors of ConvaTec Group.
More Company Research
United Homes Group, Inc. Humacyte, Inc. Kyokuyo Co., Ltd. PolyNovo Limited MNTN, Inc. Country Garden Holdings Company Limited United Natural Foods, Inc. Axcelis Technologies, Inc. Toyo Tire Corporation Gruma, S.A.B. de C.V. Morningstar, Inc. POSCO Holdings Inc. WEG S.A. BGF Retail Co., Ltd. Forsee PowerFull Company Research Reports
Looking for a more in-depth analysis of ConvaTec Group PLC? AskCyborg's Company Research section contains full AI-generated reports with detailed financials, strategic analysis, and Cyborg Score ratings. Browse the complete company research library or explore industry research reports.
AskCyborg provides AI-powered company research and analysis. Visit AskCyborg for full reports, Cyborg Score ratings, and analyst podcasts.